Invention Grant
- Patent Title: Antibodies specific to human poliovirus receptor (PVR)
-
Application No.: US16081667Application Date: 2017-02-28
-
Publication No.: US10906987B2Publication Date: 2021-02-02
- Inventor: Ofer Mandelboim , Noa S. Kaynan , Pinchas Tsukerman , Stipan Jonjic
- Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. , University of Rijeka Faculty of Medicine
- Applicant Address: IL Jerusalem; HR Rijeka
- Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.,University of Rijeka Faculty of Medicine
- Current Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.,University of Rijeka Faculty of Medicine
- Current Assignee Address: IL Jerusalem; HR Rijeka
- Agency: Rothwell, Figg, Ernst & Manbeck, P.C.
- International Application: PCT/IL2017/050256 WO 20170228
- International Announcement: WO2017/149538 WO 20170908
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/10 ; C07K14/705 ; A61K39/395 ; G01N33/574
Abstract:
The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
Public/Granted literature
- US20200040092A1 ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) Public/Granted day:2020-02-06
Information query
